VELBAN Drug Patent Profile
✉ Email this page to a colleague
When do Velban patents expire, and when can generic versions of Velban launch?
Velban is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in VELBAN is vinblastine sulfate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Velban
A generic version of VELBAN was approved as vinblastine sulfate by HIKMA on April 9th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VELBAN?
- What are the global sales for VELBAN?
- What is Average Wholesale Price for VELBAN?
Summary for VELBAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 38 |
| Clinical Trials: | 34 |
| Patent Applications: | 4,681 |
| DailyMed Link: | VELBAN at DailyMed |
Recent Clinical Trials for VELBAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| AstraZeneca | Phase 2 |
| University of Washington | Phase 2 |
| Merck Sharp & Dohme Corp. | Phase 2 |
US Patents and Regulatory Information for VELBAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | VELBAN | vinblastine sulfate | INJECTABLE;INJECTION | 012665-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
